The zebrafish model tackles anti-P2Y12 variability in humans: a translational approach

Blood Advances · Published 2026-07-21 · DOI 10.1182/bloodadvances.2025019008

Free full text

Authors (8)

Paulina Ciepla, Richard J Fish, Séverine Nolli, Sylvie Dunoyer-Geindre, Julia Charlon-Gay, Jean-Luc Reny, Marguerite Neerman-Arbez, Pierre Fontana

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ciepla, P., Fish, R., Nolli, S., et al. (2026). The zebrafish model tackles anti-P2Y12 variability in humans: a translational approach. Blood Advances. https://doi.org/10.1182/bloodadvances.2025019008

Related articles

• Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry · Blood Advances · 2026 · Same journal
• Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development · Blood Advances · 2026 · Same journal
• Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia · Blood Advances · 2026 · Same journal
• Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q · Blood Advances · 2026 · Same journal
• Reframing Hematologic and Thrombovascular Care for Transgender and Gender-Diverse Individuals: A Scoping Review · Blood Advances · 2026 · Same journal
• Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant · Blood Advances · 2026 · Same journal
• Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion dependent thalassemia in LMICs · Blood Advances · 2026 · Same journal
• A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia · Blood Advances · 2026 · Same journal
• In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway · Blood Advances · 2026 · Same journal
• JARID2 Inhibition Reprograms Human Hematopoietic Progenitor Cells To Enhance Bone Marrow Transplantation · Blood Advances · 2026 · Same journal